{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:57:21Z","timestamp":1789178241733,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have profoundly transformed the treatment landscape for microsatellite instability-high (MSI-H) colorectal cancer (CRC). However, immune-related adverse events (irAEs) remain a common and unpredictable complication among patients undergoing ICI therapy. Hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening irAE, is triggered by hyperactivated immune cells and excessive secretion of proinflammatory cytokines. We report a case of an MSI-H female patient with a history of systemic lupus erythematosus (SLE) who developed HLH after treatment with the anti-programmed cell death protein 1 (PD-1) antibody tislelizumab. After treated with tislelizumab 31 days, the patient presented with fever, pancytopenia, hemophagocytosis in bone marrow, elevated ferritin and triglyceride levels, and decreased fibrinogen. A diagnosis of HLH was confirmed with an H-score of 264. Despite steroid therapy, the patient\u2019s HLH progressed rapidly. Etoposide was deemed intolerable, and tocilizumab and immunoglobulin were declined due to financial constraints. Regrettably, the patient succumbed to HLH within 16 days of diagnosis. This is the first reported case of ICI-induced HLH in an MSI-H colon cancer patient with a history of SLE, prompting an analysis of the potential mechanisms underlying the induction of HLH in this case. Clinicians should be vigilant for the development of HLH during ICI treatment and initiate combination therapy as early as possible upon onset of HLH.<\/jats:p>","DOI":"10.3389\/fonc.2025.1585133","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:33Z","timestamp":1754453553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Pengqing","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0213","article-title":"Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients","volume":"33","author":"Dienstmann","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1038\/s41598-021-86485-8","article-title":"Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2","volume":"11","author":"Wu","year":"2021","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032314","article-title":"Predictive biomarkers of colon cancer immunotherapy: Present and future","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2017.11.001","article-title":"Systemic therapy for colon cancer","volume":"27","author":"Wu","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174322","article-title":"Beyond chemotherapy, PD-1, and HER-2: novel targets for gastric and esophageal cancer","volume":"13","author":"Siddiqui","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000224708.62510.d1","article-title":"Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome","volume":"85","author":"Lambotte","year":"2006","journal-title":"Med (Baltimore)"},{"key":"B11","first-page":"29","article-title":"Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society","volume":"18","author":"Henter","year":"1991","journal-title":"Semin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy","volume":"34","author":"Griffin","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051985","article-title":"Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: A pharmacovigilance study","volume":"12","author":"Diaz","year":"2023","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: A real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"10781552231171881","DOI":"10.1177\/10781552231171881","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review","author":"Freitas","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"von Euw","year":"2009","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v122.18","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes","volume":"122","author":"Tamamyan","year":"2016","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01499-z","article-title":"Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer","volume":"14","author":"Ofuji","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-2997","article-title":"Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659813","article-title":"ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice","volume":"127","author":"Rood","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/iai.57.2.590-595.1989","article-title":"Endotoxin-induced serum factor that stimulates gamma interferon production","volume":"57","author":"Nakamura","year":"1989","journal-title":"Infect Immun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/imr.2018.281.issue-1","article-title":"Interleukin-18: Biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.37958","article-title":"Interferon-gamma mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice","volume":"65","author":"Canna","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.605","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis and treatment","volume":"2013","author":"Janka","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-022-09285-w","article-title":"Cytokine storm and targeted therapy in hemophagocytic lymphohistiocytosis","volume":"70","author":"Zhang","year":"2022","journal-title":"Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223062","article-title":"IFN-alpha induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18822","article-title":"Exploring macrophage activation syndrome secondary to systemic lupus erythematosus in adults: A systematic review of the literature","volume":"13","author":"Aziz","year":"2021","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4719194","DOI":"10.1155\/2017\/4719194","article-title":"Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy","volume":"2017","author":"Viale","year":"2017","journal-title":"BioMed Res Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12877-023-04625-3","article-title":"Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review","volume":"24","author":"Zhai","year":"2024","journal-title":"BMC Geriatr"},{"key":"B45","doi-asserted-by":"publisher","first-page":"004370","DOI":"10.12890\/2024_004370","article-title":"Haemophagocytic lymphohistiocytosis following the anti-PD-1 nivolumab in a patient with gastric cancer and ankylosing spondylitis","volume":"11","author":"Long","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.035","article-title":"Association of hemophagocytic lymphohistiocytosis and programmed death 1 checkpoint inhibitors","volume":"14","author":"Laderian","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-154","article-title":"Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review","volume":"11","author":"Wei","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa750","article-title":"First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors","volume":"60","author":"Azari","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"101097","DOI":"10.1016\/j.rmcr.2020.101097","article-title":"A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy","volume":"30","author":"Takahashi","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2169\/internalmedicine.1001-18","article-title":"Pembrolizumab-induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in non-small cell lung cancer","volume":"58","author":"Okawa","year":"2019","journal-title":"Intern Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40425-018-0384-0","article-title":"Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab","volume":"6","author":"Hantel","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw537","article-title":"Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression","volume":"28","author":"Takeshita","year":"2017","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"6631859","DOI":"10.1155\/2021\/6631859","article-title":"Response to treatment with an anti-interleukin-6 receptor antibody (Tocilizumab) in a patient with hemophagocytic syndrome secondary to immune checkpoint inhibitors","volume":"2021","author":"Olivares-Hernandez","year":"2021","journal-title":"Case Rep Oncol Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1159\/000507281","article-title":"Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma","volume":"13","author":"Thummalapalli","year":"2020","journal-title":"Case Rep Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2101","article-title":"Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis","volume":"31","author":"Ozdemir","year":"2020","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx701","article-title":"Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors","volume":"29","author":"Michot","year":"2018","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40425-019-0582-4","article-title":"Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report","volume":"7","author":"Honjo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14712\/23362936.2022.4","article-title":"Effective treatment of a melanoma patient with hemophagocytic lymphohistiocytosis after nivolumab and ipilimumab combined immunotherapy","volume":"123","author":"Pacholczak-Madej","year":"2022","journal-title":"Prague Med Rep"},{"key":"B59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/jmedgenet-2018-105485","article-title":"Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism","volume":"56","author":"Al-Samkari","year":"2019","journal-title":"J Med Genet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-018-0365-3","article-title":"Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report","volume":"6","author":"Sadaat","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.v11.4","article-title":"Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis in a patient with non-small cell lung carcinoma","volume":"11","author":"Oyama","year":"2023","journal-title":"Respirol Case Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v193.6","article-title":"Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis","volume":"193","author":"Choi","year":"2021","journal-title":"Br J Haematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mdx113","article-title":"Pembrolizumab associated hemophagocytic lymphohistiocytosis","volume":"28","author":"Shah","year":"2017","journal-title":"Ann Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41199-020-0050-3","article-title":"Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge","volume":"5","author":"Kalmuk","year":"2020","journal-title":"Cancers Head Neck"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13321","article-title":"Hemophagocytic lymphohistiocytosis with advanced Malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review","volume":"33","author":"Mizuta","year":"2020","journal-title":"Dermatol Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3889-19","article-title":"Hemophagocytic lymphohistiocytosis in a patient with rheumatoid arthritis on pembrolizumab for lung adenocarcinoma","volume":"59","author":"Akagi","year":"2020","journal-title":"Intern Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"100263","DOI":"10.1016\/j.jtocrr.2021.100263","article-title":"Marked, lasting disease regression and concomitantly induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in a patient with lung adenocarcinoma and autoantibodies receiving atezolizumab plus chemotherapy: A case report","volume":"3","author":"Endo","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.063","article-title":"Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab","volume":"93","author":"Satzger","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1585133\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:35Z","timestamp":1754453555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1585133\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":68,"alternative-id":["10.3389\/fonc.2025.1585133"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1585133","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1585133"}}